{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:04:19Z","timestamp":1790741059727,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmune hepatitis (AIH) is a rare chronic liver disease. Impaired health-related quality of life (HRQL) contributes to the overall disease burden. At current, only limited data related to the impact of treatment response on HRQL are available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of the study was to determine the impact of biochemical remission on HRQL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with AIH were prospectively enrolled between July 2018 and June 2019. A liver disease-specific tool, the chronic liver disease questionnaire (CLDQ) and the generic EQ-5D-5L were used to quantify HRQL. Treatment response was assessed biochemically by measurement of immunoglobulin G, ALT and AST. The cohort was divided into two groups according to their biochemical remission status in either complete vs. incomplete remission. Clinical as well as laboratory parameters and comorbidities were analysed using univariable and multivariable analysis to identify predictors of poor HRQL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 116 AIH patients were included (median age: 55; 77.6% female), of which 9.5% had liver cirrhosis. In this cohort, 38 (38.4%) showed a complete and 61 (61.6%) an incomplete biochemical remission at study entry. The HRQL was significantly higher in patients with a complete as compared to an incomplete biochemical remission (CLDQ overall score: 5.66\u2009\u00b1\u20091.15 vs. 5.10\u2009\u00b1\u20091.35;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). In contrast, the generic EQ-5D-5L UI-value was not different between the groups. Multivariable analysis identified AST (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) and an incomplete biochemical remission (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) as independent predictors of reduced HRQL (CLDQ total value).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with a complete biochemical remission had a significantly higher HRQL. Liver-related quality of life in patients living with AIH is dependent on the response to immunosuppressive treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11136-021-02850-0","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T01:02:30Z","timestamp":1620781350000},"page":"2853-2861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Health-related quality of life in patients with autoimmune hepatitis"],"prefix":"10.1007","volume":"30","author":[{"given":"Maurice","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Grambihler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Labenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Kaps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus-Alexander","family":"W\u00f6rns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"key":"2850_CR1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1046\/j.1440-1746.2003.03165.x","volume":"18","author":"JJ Feld","year":"2003","unstructured":"Feld, J. J., & Heathcote, E. J. (2003). Epidemiology of autoimmune liver disease. Journal of Gastroenterology and Hepatology, 18, 1118\u20131128","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"2850_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMra050408","volume":"354","author":"EL Krawitt","year":"2006","unstructured":"Krawitt, E. L. (2006). Autoimmune hepatitis. New England Journal of Medicine, 354, 54\u201366","journal-title":"New England Journal of Medicine"},{"key":"2850_CR3","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","volume":"49","author":"NMF van Gerven","year":"2014","unstructured":"van Gerven, N. M. F., Verwer, B. J., Witte, B. I., van Erpecum, K. J., van Buuren, H. R., Maijers, I., Visscher, A. P., Verschuren, E. C., van Hoek, B., Coenraad, M. J., & Beuers, U. H. (2014). Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scandinavian Journal of Gastroenterology, 49, 1245\u20131254","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"2850_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","volume":"53","author":"MMH Lamers","year":"2010","unstructured":"Lamers, M. M. H., van Oijen, M. G. H., Pronk, M., & Drenth, J. P. (2010). Treatment options for autoimmune hepatitis: A systematic review of randomized controlled trials. Journal of Hepatology, 53, 191\u2013198","journal-title":"Journal of Hepatology"},{"key":"2850_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cld.816","volume":"14","author":"C Schramm","year":"2019","unstructured":"Schramm, C. (2019). Autoimmune hepatitis beyond steroids: Effective trial design and attention to quality of life. Clinical Liver Disease (Hoboken), 14, 33\u201336","journal-title":"Clinical Liver Disease (Hoboken)"},{"key":"2850_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/liv.13458","volume":"38","author":"M Sebode","year":"2018","unstructured":"Sebode, M., Hartl, J., Vergani, D., Lohse, A. W., & International Autoimmune Hepatitis Group (IAIHG). (2018). Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. Liver International, 38, 15\u201322","journal-title":"Liver International"},{"key":"2850_CR7","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","volume":"140","author":"B Hoeroldt","year":"2011","unstructured":"Hoeroldt, B., McFarlane, E., Dube, A., Basumani, P., Karajeh, M., Campbell, M. J., & Gleeson, D. (2011). Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology, 140, 1980\u20131989","journal-title":"Gastroenterology"},{"key":"2850_CR8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"EASL Clinical Practice Guidelines","year":"2015","unstructured":"EASL Clinical Practice Guidelines. (2015). Autoimmune hepatitis. Journal of Hepatology, 63, 971\u20131004","journal-title":"Journal of Hepatology"},{"key":"2850_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2019","unstructured":"Mack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2019). Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. Hepatology, 72, 671\u2013722","journal-title":"Hepatology"},{"key":"2850_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jhep.2013.10.035","volume":"60","author":"C Schramm","year":"2014","unstructured":"Schramm, C., Wahl, I., Weiler-Normann, C., Voigt, K., Wiegard, C., Glaubke, C., Br\u00e4hler, E., L\u00f6we, B., Lohse, A. W., & Rose, M. (2014). Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. Journal of Hepatology, 60, 618\u2013624","journal-title":"Journal of Hepatology"},{"key":"2850_CR11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jhep.2012.07.032","volume":"57","author":"S Sockalingam","year":"2012","unstructured":"Sockalingam, S., Blank, D., Abdelhamid, N., Abbey, S. E., & Hirschfield, G. M. (2012). Identifying opportunities to improve management of autoimmune hepatitis: Evaluation of drug adherence and psychosocial factors. Journal of Hepatology, 57, 1299\u20131304","journal-title":"Journal of Hepatology"},{"key":"2850_CR12","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/hep.30031","volume":"68","author":"LL Wong","year":"2018","unstructured":"Wong, L. L., Fisher, H. F., Stocken, D. D., Rice, S., Khanna, A., Heneghan, M. A., Oo, Y. H., Mells, G., Kendrick, S., Dyson, J. K., & Jones, D. E. (2018). The impact of autoimmune hepatitis and its treatment on health utility. Hepatology, 68, 1487\u20131497","journal-title":"Hepatology"},{"key":"2850_CR13","doi-asserted-by":"publisher","first-page":"e0204772","DOI":"10.1371\/journal.pone.0204772","volume":"13","author":"A Takahashi","year":"2018","unstructured":"Takahashi, A., Moriya, K., Ohira, H., Arinaga-Hino, T., Zeniya, M., Torimura, T., Abe, M., Takaki, A., Kang, J. H., Inui, A., & Fujisawa, T. (2018). Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey. PLoS One, 13, e0204772","journal-title":"PLoS One"},{"key":"2850_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/liv.13960","volume":"39","author":"MK Janik","year":"2019","unstructured":"Janik, M. K., Wunsch, E., Raszeja-Wyszomirska, J., Moskwa, M., Kruk, B., Krawczyk, M., & Milkiewicz, P. (2019). Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: A prospective, single-centre study. Liver International, 39, 215\u2013221","journal-title":"Liver International"},{"key":"2850_CR15","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010). Diagnosis and management of autoimmune hepatitis. Hepatology, 51, 2193\u20132213","journal-title":"Hepatology"},{"key":"2850_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/gut.45.2.295","volume":"45","author":"ZM Younossi","year":"1999","unstructured":"Younossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999). Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut, 45, 295\u2013300","journal-title":"Gut"},{"key":"2850_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1524-4733.2007.00230.x","volume":"11","author":"MF Janssen","year":"2008","unstructured":"Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value in Health, 11, 275\u2013284","journal-title":"Value in Health"},{"key":"2850_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","volume":"36","author":"K Ludwig","year":"2018","unstructured":"Ludwig, K., Graf von der Schulenburg, J.-M., & Greiner, W. (2018). German value set for the EQ-5D-5L. Pharmacoeconomics, 36, 663\u2013674","journal-title":"Pharmacoeconomics"},{"key":"2850_CR19","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1097\/MCG.0000000000001149","volume":"53","author":"C Labenz","year":"2019","unstructured":"Labenz, C., Toenges, G., Schattenberg, J. M., Nagel, M., Sprinzl, M. F., Nguyen-Tat, M., Zimmermann, T., Huber, Y., Marquardt, J. U., Galle, P. R., & W\u00f6rns, M. A. (2019). Clinical predictors for poor quality of life in patients with covert hepatic encephalopathy. Journal of Clinical Gastroenterology, 53, e303\u2013e307","journal-title":"Journal of Clinical Gastroenterology"},{"key":"2850_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11136-006-9131-y","volume":"16","author":"SM van der Plas","year":"2007","unstructured":"van der Plas, S. M., Hansen, B. E., de Boer, J. B., Stijnen, T., Passchier, J., Rob, A., & Schalm, S. W. (2007). Generic and disease-specific health related quality of life of liver patients with various aetiologies: A survey. Quality of Life Research, 16, 375\u2013388","journal-title":"Quality of Life Research"},{"key":"2850_CR21","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","volume":"17","author":"Y Huber","year":"2019","unstructured":"Huber, Y., Boyle, M., Hallsworth, K., Tiniakos, D., Straub, B. K., Labenz, C., Ruckes, C., Galle, P. R., Romero-G\u00f3mez, M., Anstee, Q. M., & Schattenberg, J. M. (2019). Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clinical Gastroenterology and Hepatology, 17, 2085\u20132092.e1","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2850_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/apt.15111","volume":"49","author":"JK Dyson","year":"2019","unstructured":"Dyson, J. K., de Martin, E., Dalekos, G. N., Drenth, J. P., Herkel, J., Hubscher, S. G., Kelly, D., Lenzi, M., Milkiewicz, P., Oo, Y. H., & Heneghan, M. A. (2019). Review article: Unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Alimentary Pharmacology & Therapeutics, 49, 528\u2013536","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"2850_CR23","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1080\/08870446.2011.565876","volume":"26","author":"L Montali","year":"2011","unstructured":"Montali, L., Frigerio, A., Riva, P., & Invernizzi, P. (2011). \u2018It\u2019s as if PBC didn\u2019t exist\u2019: The illness experience of women affected by primary biliary cirrhosis. Psychology & Health, 26, 1429\u20131445","journal-title":"Psychology & Health"},{"key":"2850_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11684-015-0386-y","volume":"9","author":"F Sahebjam","year":"2015","unstructured":"Sahebjam, F., & Vierling, J. M. (2015). Autoimmune hepatitis. Frontiers in Medicine, 9, 187\u2013219","journal-title":"Frontiers in Medicine"},{"key":"2850_CR25","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.cgh.2008.08.018","volume":"6","author":"T Al-Chalabi","year":"2008","unstructured":"Al-Chalabi, T., Underhill, J. A., Portmann, B. C., McFarlane, I. G., & Heneghan, M. A. (2008). Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clinical Gastroenterology and Hepatology, 6, 1389\u20131395","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2850_CR26","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jhep.2014.06.034","volume":"61","author":"JG Orr","year":"2014","unstructured":"Orr, J. G., Homer, T., Ternent, L., Newton, J., McNeil, C. J., Hudson, M., & Jones, D. E. (2014). Health related quality of life in people with advanced chronic liver disease. Journal of Hepatology, 61, 1158\u20131165","journal-title":"Journal of Hepatology"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-02850-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-021-02850-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-02850-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T14:31:11Z","timestamp":1632925871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-021-02850-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1007\/s11136-021-02850-0","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"16 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JMS has acted as consultant to Boehringer Ingelheim, BMS, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Madrigal, Novartis, Novo Nordisk, Nordic Bioscience, Pfizer, Roche, Sanofi, Siemens Healthcare GmbH. Research Funding: Gilead Sciences, Boehringer Ingelheim. Speakers Bureau: Falk Foundation MSD Sharp & Dohme GmbH. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}